Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New taxoid RPR-109881A evaluated in phase I trial in patients with solid tumors

Sep. 12, 2000

Yamanouchi discovers naturally occurring cytotoxic depsipeptide

Sep. 8, 2000

Pharmacia's Aromasin receives clearance from Health Canada

Sep. 7, 2000

Bayer investigates inhibition of raf kinase signaling pathway as new approach to cancer

Sep. 6, 2000

New antitumor compound from Banyu produced by microorganism

Sep. 5, 2000

MEK inhibitors and their use described in recent patents

Sep. 5, 2000

PARP inhibitors reportedly useful in combination with cytotoxic agents

Sep. 5, 2000

Taxotere combination therapy approved in E.U. for treatment of advanced breast cancer

Sep. 5, 2000

SuperGen updates progress of phase III rubitecan trials

Sep. 4, 2000

Arimidex approved by FDA as first-line therapy of breast cancer

Sep. 4, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
Gensci-134: a long-acting growth hormone receptor agonist fusion protein
BioWorld Science
Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone...